Имитаторы васкулита. Часть 2. Имитация васкулита крупных и средних сосудов: генетические васкулопатии. Имитация васкулита мелких сосудов

Генетические васкулопатии могут имитировать васкулит крупных и средних сосудов, а окклюзионные неваскулитные васкулопатии и инфекции часто становятся имитаторами васкулита мелких и средних сосудов. Большинство этих состояний являются не менее тяжелыми заболеваниями, чем системные васкулиты, но требуют принципиально другой, часто неотложной терапии.

1. Milewicz DM, Braverman AC, De Backer J, et al. Marfan syndrome. Nat Rev Dis Primers. 2021 Sep 2;7(1):64. doi: 10.1038/s41572-021-00298-7.

2. Loeys BL, Dietz HC, Braverman AC, et al. The revised Ghent nosology for the Marfan syndrome. J Med Genet. 2010 Jul;47(7): 476-85. doi: 10.1136/jmg.2009.072785.

3. de Beaufort HWL, Trimarchi S, Korach A, et al. Aortic dissection in patients with Marfan syndrome based on the IRAD data. Ann Cardiothorac Surg. 2017 Nov;6(6):633-641. doi: 10.21037/acs.2017.10.03.

4. Malfait F, Francomano C, Byers P, et al. 2017 international classification of the Ehlers–Danlos syndromes. Am J Med Genet C Semin Med Genet. 2017 Mar;175(1):8-26. doi: 10.1002/ajmg.c.31552.

5. Blinc A, Maver A, Rudolf G, et al. Clinical Exome Sequencing as a Novel Tool for Diagnosing Loeys–Dietz Syndrome Type 3. Eur J Vasc Endovasc Surg. 2015 Dec;50(6):816-21. doi: 10.1016/j.ejvs.2015.08.003.

6. MacCarrick G, Black JH 3rd, Bowdin S, et al. Loeys-Dietz syndrome: a primer for diagnosis and management. Genet Med. 2014 Aug;16(8):576-87. doi: 10.1038/gim.2014.11.

7. Casey K, Zayed M, Greenberg JI, et al. Endovascular repair of bilateral iliac artery aneurysms in a patient with Loeys–Dietz syndrome. Ann Vasc Surg. 2012 Jan;26(1):107. e5-10. doi: 10.1016/j.avsg.2011.06.005.

8. Asta L, D'Angelo GA, Marinelli D, et al. Basis, New Diagnostic Approaches, and Updated Therapeutic Strategies of the Syndromic Aortic Diseases: Marfan, Loeys–Dietz, and Vascular Ehlers–Danlos Syndrome. Int J Environ Res Public Health. 2023 Aug 20; 20(16):6615. doi: 10.3390/ijerph20166615.

9. Anderson JL, Gutmann DH. Neurofibromatosis type 1. Handb Clin Neurol. 2015;132: 75-86. doi: 10.1016/B978-0-444-62702-5.00004-4.

10. Brosius SN, Vossough A, Fisher MJ, et al. Characteristics of Moyamoya Syndrome in Pediatric Patients With Neurofibromatosis Type 1. Pediatr Neurol. 2022 Sep;134:85-92. doi: 10.1016/j.pediatrneurol.2022.05.013.

11. Lecleire-Collet A, Cohen SY, Vignal C, et al. Retinal ischaemia in type 1 neurofibromatosis. Br J Ophthalmol. 2006 Jan;90(1):117. doi: 10.1136/bjo.2005.077701.

12. Byers PH, Belmont J, Black J, et al. Diagnosis, natural history, and management in vascular Ehlers–Danlos syndrome. Am J Med Genet C Semin Med Genet. 2017 Mar;175(1): 40-47. doi: 10.1002/ajmg.c.31553.

13. Sklar LR, Messman A. An Atypical Case of Warfarin-Induced Skin Necrosis. Clin Pract Cases Emerg Med. 2017 Oct 11;1(4):359-361. doi: 10.5811/cpcem.2017.3.33373.

14. Chan YC, Valenti D, Mansfield AO et al. Warfarin induced skin necrosis. Br J Surg. 2000 Mar;87(3):266-72. doi: 10.1046/j.1365-2168.2000.01352.x.

15. Kakagia DD, Papanas N, Karadimas E, et al. Warfarin-induced skin necrosis. Ann Dermatol. 2014 Feb;26(1):96-8. doi: 10.5021/ad.2014.26.1.96.

16. Nazarian RM, Van Cott EM, Zembowicz A, et al. Warfarin-induced skin necrosis. J Am Acad Dermatol. 2009 Aug;61(2):325-32. doi: 10.1016/j.jaad.2008.12.039.

17. Ivascu NS, Fitzgerald M, Ghadimi K, et al. Heparin-induced thrombocytopenia: a review for cardiac anesthesiolo-gists and intensivists. J Cardiothorac Vasc Anesth. 2019 Feb;33(2):511-520. doi: 10.1053/j.jvca.2018.10.035. Epub 2018 Oct 26.

18. Warkentin TE. Clinical picture of heparininduced thrombocytopenia. In: Warkentin TE, Greinacher A, editors. Heparin-Induced Thrombocytopenia. 2nd ed. New York: Marcel Dekker Inc; 2001. P. 43–86.

19. Cosmi B. Current management of heparin-induced thrombocytopenia. Expert Rev Hematol. 2015 Dec;8(6):837-49. doi: 10.1586/17474086.2015.1087845.

20. Васильев СА, Горгидзе ЛА, Моисеева ТН и др. Гепарининдуцированная тромбоцитопения (обзор). Атеротромбоз. 2019; (1):99-114.

21. Di Giacomo TB, Hussein TP, Souza DG, et al. Frequency of thrombophilia determinant factors in patients with livedoid vasculopathy and treatment with anticoagulant drugs – a prospective study. J Eur Acad Dermatol Venereol. 2010 Nov;24(11):1340-6. doi: 10.1111/j.1468-3083.2010.03646.x.

22. Gao Y, Jin H. Plasminogen activator inhibitor-1: a potential etiological role in livedoid vasculopathy. Int Wound J. 2020 Dec; 17(6):1902-1908. doi: 10.1111/iwj.13480.

23. Vasudevan B, Neema S, Verma R. Livedoid vasculopathy: A review of pathogenesis and principles of management. Indian J Dermatol Venereol Leprol. 2016 Sep-Oct;82(5): 478-88. doi: 10.4103/0378-6323.183635.

24. Soulages A, Maisonobe T, Auzou P, et al. Peripheral neuropathy and livedoid vasculopathy. J Neurol. 2022 Jul;269(7):3779-3788. doi: 10.1007/s00415-022-11007-z.

25. Kelly RI, Wee E, Gan C. Re: Letter from the Editor: Management of cutaneous polyarteritis nodosa. J Am Acad Dermatol. 2023 Jul;89(1):e63-e64. doi: 10.1016/j.jaad.2023.03.011.

26. Burg MR, Mitschang C, Goerge T, et al. Livedoid vasculopathy – A diagnostic and therapeutic challenge. Front Med (Lausanne). 2022 Oct 3;9:1012178. doi: 10.3389/fmed.2022.1012178.

27. Alavi A, Hafner J, Dutz JP, et al. Livedoid vasculopathy: an in-depth analysis using a modified Delphi approach. J Am Acad Dermatol. 2013 Dec;69(6):1033-1042.e1. doi: 10.1016/j.jaad.2013.07.019.

28. Nigwekar SU, Thadhani R, Brandenburg VM. Calciphylaxis. N Engl J Med. 2018 May 3;378(18):1704-1714. doi: 10.1056/NEJMra1505292.

29. Gabel CK, Nguyen ED, Chakrala T, et al. Assessment of outcomes of calciphylaxis. J Am Acad Dermatol. 2021 Oct;85(4):1057-1064. doi: 10.1016/j.jaad.2020.10.067.

30. Chinnappan J, Aguirre J, Marcus H, et al. Fatal Case of Systemic Calciphylaxis in the Gastrointestinal Tract: A Case Report and Literature Review. Cureus. 2023 Mar 24;15(3): e36641. doi: 10.7759/cureus.36641.

31. https://www.ncbi.nlm.nih.gov/books/NBK519020/

32. Lajoie C, Ghanemi A, Bourbeau K, et al. Multimodality approach to treat calciphylaxis in end-stage kidney disease patients. Ren Fail. 2023;45(2):2256413. doi: 10.1080/0886022X.2023.2256413. Epub 2023 Sep 19.

33. Ozkok A. Cholesterol-embolization syndrome: current perspectives. Vasc Health Risk Manag. 2019 Jul 8;15:209-220. doi: 10.2147/VHRM.S175150.

34. Scolari F, Ravani P. Atheroembolic renal disease. Lancet. 2010 May 8;375(9726): 1650-60. doi: 10.1016/S0140-6736(09)62073-0. Epub 2010 Apr 8.

35. Mulay SR, Anders HJ. Crystallopathies. N Engl J Med. 2016 Jun 23;374(25):2465-76. doi: 10.1056/NEJMra1601611.

36. Agrawal A, Ziccardi MR, Witzke C, et al. Cholesterol embolization syndrome: An under-recognized entity in cardiovascular interventions. J Interv Cardiol. 2018 Jun;31(3): 407-415. doi: 10.1111/joic.12483.

37. Ghanem F, Vodnala D, Kalavakunta JK, et al. Cholesterol crystal embolization following plaque rupture: a systemic disease with unusual features. J Biomed Res. 2017 Jan 19; 31(2):82-94. doi: 10.7555/JBR.31.20160100.

38. Ponzoni M, Campo E, Nakamura S. Intravascular large B-cell lymphoma: a chameleon with multiple faces and many masks. Blood. 2018 Oct 11;132(15):1561- 1567. doi: 10.1182/blood-2017-04-737445.

39. Shinkawa Y, Hatachi S, Yagita M. Intravascular large B-cell lymphoma with a high titer of proteinase-3-anti-neutrophil cytoplasmic antibody mimicking granulomatosis with polyangiitis. Mod Rheumatol. 2019 Jan;29(1):195-197. doi: 10.1080/14397595.2016.1205798.

40. Sugiyama A, Kobayashi M, Daizo A, et al. Diffuse Cerebral Vasoconstriction in a Intravascular Lymphoma Patient with a High Serum MPO-ANCA Level. Intern Med. 2017;56(13):1715-1718. doi: 10.2169/internalmedicine.56.8051. Epub 2017 Jul 1.

41. Krishnan P, Rajaraman K, Chowdhury SR, et al. Multiple fusiform distal aneurysms in an operated case of atrial myxoma: case report and review of literature. Neurol India. 2013 Mar-Apr;61(2):184-5. doi: 10.4103/0028-3886.111149.

42. Moreno-Ariсo M, Ortiz-Santamaria V, Deudero Infante A, et al. A classic mimicker of systemic vasculitis. Reumatol Clin. 2016 Mar-Apr;12(2):103-6. doi: 10.1016/j.reuma.2015.03.006.

43. Jougasaki M, Takenoshita Y, Umebashi K, et al. Autocrine Regulation of Interleukin-6 via the Activation of STAT3 and Akt in Cardiac Myxoma Cells. Int J Mol Sci. 2024 Feb 13;25(4):2232. doi: 10.3390/ijms25042232.

44. Cahill TJ, Prendergast BD. Infective endocarditis. Lancet. 2016 Feb 27;387(10021): 882-93. doi: 10.1016/S0140-6736(15)00067-7. Epub 2015 Sep 1.

45. Aslangul E. Antineutrophil cytoplasmic antibody positivity in gram-positive and Bartonella-induced infective endocarditis: comment on the article by Mahr et al. Arthritis Rheumatol. 2015 May;67(5):1407-8. doi: 10.1002/art.39046.

46. Van Gool IC, Kers J, Bakker JA, et al. Antineutrophil cytoplasmic antibodies in infective endocarditis: a case report and systematic review of the literature. Clin Rheumatol. 2022 Oct;41(10):2949-2960. doi: 10.1007/s10067-022-06240-w.

47. Bonaci-Nikolic B, Andrejevic S, Pavlovic M, et al. Prolonged infections associated with antineutrophil cytoplasmic antibodies specific to proteinase 3 and myeloperoxidase: diagnostic and therapeutic challenge. Clin Rheumatol. 2010 Aug;29(8):893-904. doi: 10.1007/s10067-010-1424-4.

48. Houben E, Bax WA, van Dam B, et al. Diagnosing ANCA-associated vasculitis in ANCA positive patients: A retrospective analysis on the role of clinical symptoms and the ANCA titre. Medicine (Baltimore). 2016 Oct;95(40):e5096. doi: 10.1097/MD.0000000000005096.

49. Chalkia A, Thomas K, Giannou P, et al. Hypocomplementemia is associated with more severe renal disease and worse renal outcomes in patients with ANCA-associated vasculitis: a retrospective cohort study. Ren Fail. 2020 Nov;42(1):845-852. doi: 10.1080/0886022X.2020.1803086.

50. Cervi A, Kelly D, Alexopoulou I, et al. ANCA-associated pauci-immune glomerulonephritis in a patient with bacterial endocarditis: a challenging clinical dilemma. Clin Nephrol Case Stud. 2017 Apr 26;5:32-37. doi: 10.5414/CNCS109076.

51. Hermann J, Demel U, Stünzner D, et al. Clinical interpretation of antineutrophil cytoplasmic antibodies: parvovirus B19 infection as a pitfall. Ann Rheum Dis. 2005 Apr;64(4): 641-3. doi: 10.1136/ard.2004.024877.

52. Menter T, Haslbauer JD, Nienhold R, et al. Postmortem examination of COVID-19 patients reveals diffuse alveolar damage with severe capillary congestion and variegated findings in lungs and other organs suggesting vascular dysfunction. Histopathology. 2020 Aug;77(2):198-209. doi: 10.1111/his.14134.

53. Choi H, Park YB, Song J, et al. Unclassifiable repeated antineutrophil cytoplasmic antibody (ANCA) positivity in diseases other than ANCA-associated vasculitis. Z Rheumatol. 2022 Oct;81(8):705-711. doi: 10.1007/s00393-021-00998-1. Epub 2021 Apr 27.